EDITORIALS. Do cancer drugs improve survival or quality of life? 'Patient commentary: the current model has failed'

Area of Science:

• Pharmacology
• Clinical Trials
• Health Economics

Background:

• The approval process for new pharmaceuticals is extensive.
• Assessing the real-world benefit of new drugs is crucial for patient care.
• Existing literature suggests a potential disconnect between drug approval and demonstrated patient benefit.

Purpose of the Study:

• To evaluate the evidence supporting the market entry of new drugs.
• To determine if new drugs demonstrate significant benefits in survival or quality of life.
• To critically assess the standards for drug efficacy in regulatory approvals.

Main Methods:

• Systematic review of drug approval data.
• Analysis of clinical trial outcomes for survival and quality of life metrics.
• Comparative analysis of pre- and post-market evidence for drug efficacy.

Main Results:

• A significant proportion of drugs were approved without robust evidence of improved survival.
• Many pharmaceuticals lacked data demonstrating a positive impact on patients' quality of life.
• The evidence base for benefit was often limited at the time of market entry.

Conclusions:

• The current system allows drugs to enter the market with insufficient evidence of clinical benefit.
• There is a need to strengthen the requirements for demonstrating survival or quality of life improvements.
• Re-evaluation of drug approval criteria is necessary to ensure patient-centered outcomes.